Trial · NCT07902219
Qurse Revand for MASLD: A Randomized Controlled Safety and Efficacy Trial
NCT07902219, Phase 2, Not yet recruiting, National Institute of Unani Medicine, Bengaluru
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Qurse Revand for MASLD: A Randomized Controlled Safety and Efficacy Trial. Trials, record NCT07902219. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07902219
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Qurse Revand for MASLD: A Randomized Controlled Safety and Efficacy Trial
- NCT number
- NCT07902219
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 128 participants, estimated
- Lead sponsor
- National Institute of Unani Medicine, Bengaluru
- Conditions
- MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
- Interventions
- Qurse Revand, Placebo
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Fatty Liver Grading by USG | From enrollment to the end of treatment at 60 Days | Changes /decrease in fatty liver grading(from grade 1,2 to grade 0,1)by USG |
| Secondary | Change in Fatty Liver Index (FLI) | From enrollment to the end of treatment at 60 days | Change/Decrease in fatty liver Index. FLI calculates a score ranging from 0 to 100 using four routinely measured parameters. FLI Score Interpretation: (FLI \< 30 = Low Probability, 30 ≤ FLI \< 60 =Intermediate / Indeterminate, FLI ≥ 60= High Probability ) |
| Secondary | Change in Lipid Profile | From enrollment to the end of treatment at 60 days | Change in serum Triglycerides levels(mg/dL or mmol/L) \&Change in serum High-Density Lipoprotein (HDL) Cholesterol(mg/dL or mmol/L) |
| Secondary | Changes in Health-related quality of life using EuroQol-5D (EQ-5D) | From enrollment to the end of treatment at 60 days | The EQ-5D consists of two main components: 1. EQ-5D Index Score (Utility Score): How it is calculated: The combinations from the 5 dimensions are converted into a single summary index using population-specific country value sets. Scale Range: Typically spans from 1.0 (Full/Perfect Health) to 0.0 (A state equivalent to death). Negative values are possible for health states valued as worse than death. 2. EQ Visual Analogue Scale (EQ-VAS): A 0-100 rating scale measuring overall perceived health (100 = best,0 = worst). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07902219
GET https://conductscience.org/api/trials/v1/NCT07902219/registered